Syngene International Limited

📌Meet us at CPHI Milan (October 8-10, 2024, Booth #7C114) and explore how we can transform your ideas into market-ready solutions. Ready to accelerate your HPAPI projects? Book your meeting now! Link in comments. 🔗 At Syngene, our state-of-the-art facilities and technology are tailored to meet the rigorous demands of high potent compound development and manufacturing. Our expertise spans the entire spectrum of small molecule HPAPI development, from initial concept through to commercial production. Key highlights of our manufacturing units: Bangalore site: • The USFDA & PMDA approved GMP manufacturing facility at Syngene's Bangalore campus is designed to handle cytotoxic and cytostatic high potent APIs up to [OEB-4]. • It boasts a production capacity of up to 20 kg of API per batch. • The site includes a state-of-the-art process development and analytical development laboratory, capable of handling high potent compounds up to [OEB-5]. Mangalore site: • The USFDA approved GMP manufacturing facility at Syngene's Mangalore campus is designed to handle high potent intermediates and regulatory starting materials up to 0.1 µg/m³ over 8 hours [OEB-4]. • The facility is designed to produce up to 300 kg of intermediates per batch. Shared features of both sites: • Our high potent facilities are equipped with Distributed Control System (DCS) technology. • Zero liquid and solid discharge facilities, featuring the most advanced effluent treatment plants. • Reactors are made from various materials of construction, including SS316, MSGL, and Hastelloy, with operational parameters ranging from -70°C to 140°C. #SyngeneInnovation #HPAPIExcellence #CPHIMilan2024 #DrugDevelopment

⭐Did you know that successful technology transfer in biologics manufacturing can save time, resources, and potentially impact patient safety? Syngene International, a leading global CRDMO, has developed a unique '100% first time right' approach to technology transfer in biologics manufacturing. This innovative method involves: •A risk-based assessment of incoming data •Using Decision Trees to evaluate confidence levels in processes and analytical methods •Creating detailed Technology Transfer approach documents The result? A track record of consistent yields and successful transfers, regardless of differences in infrastructure, equipment, or processes between sites. Want to learn more about achieving biologics manufacturing milestones through effective technology transfer? Read the full viewpoint in the link provided in comments section! 🔗 #BiologicsManufacturing #TechnologyTransfer #Pharma #Biotechnology #CRDMO

🌟 Are you looking to advance your oligonucleotide research? 🌟 We offer a full range of services from discovery to cGMP manufacturing, enabling rapid development at lower costs. We specialize in chemically synthesized high-quality modified and non-modified custom oligonucleotide (DNA/RNA), siRNA (single & double-stranded, miRNA (modified and non-modified), and antisense oligonucleotides, at various scales with rapid turnaround time. Together with our state-of-the-art oligonucleotide facility, a highly qualified team of scientists, and global client experience, we have all it takes to become the partner of choice for companies looking to accelerate their oligonucleotide programs. Explore our services and see how we can support your next breakthrough! For more details, visit the link in comments section 🔗 #Syngene #Oligonucleotides #Biotech #CRDMO

Bile-iant Innovation: Cholestatic Disease Treatment   A prominent biotech company collaborated with Syngene to develop a first-in-class inhibitor targeting cholestatic diseases. Through cutting-edge medicinal chemistry and rigorous profiling, our team identified a potent molecule that reduces bile acid concentration, marking significant progress in treating this condition. The novel drug is now advancing to preclinical development, showcasing the power of strategic partnerships in accelerating drug discovery and development. Read the full case study 👉 link in the comments section 🔗 #NASH #Noveldrug #DMPK #ADME   

The International Animal Health Journal has featured Syngene in an article titled “The Importance of Strategic Investments and Technological Advancements.” In the article, Alex Del Priore, SVP - Manufacturing Services at Syngene emphasizes the importance of strong CDMO partnerships built on trust, quality, compliance, and effective communication. He also discusses the agility and flexibility needed to adapt to market demands and regulations. The piece highlights Syngene's decade-long partnership with Zoetis, showcasing the Company's infrastructure, technical expertise, and scalable manufacturing facilities as key differentiators. Read the full article 👉 link in the comments section. 🔗

Enhance your Animal Health Research with Syngene!   Discover Syngene's comprehensive solutions for the animal health industry. Our state-of-the-art facilities and expert teams are dedicated to advancing veterinary science through innovative research and development—partner with us to achieve excellence in animal health and ensure the well-being of animals worldwide. To learn more about our capabilities and how we can support your animal health initiatives, visit the link in the comments section. 🔗 #AnimalHealth #VeterinaryScience #Biotech #Syngene #Innovation  

📌 Accelerate your drug discovery program with our comprehensive ADME-DMPK services. Syngene's ADME-DMPK services offer cost-effective, high-quality data for drug discovery and development, supported by our expert scientists. Our cutting-edge infrastructure accelerates bioanalytical data processing, including ultra-performance liquid chromatography (UPLC) and time-of-flight (Tof) mass spectrometry. We provide in vitro ADME and in vivo pharmacokinetics (PK) studies as stand-alone projects or within an integrated drug discovery (IDD) program. For more information, contact our experts 👉 link comments section 🔗 #SyngeneDrugDiscovery #Pharmacokinetics #ADMEDMPK #Bioanalytical

📌 Compound Management Services. Accelerate your drug discovery programs with our comprehensive, state-of-the-art, centralized Compound Management facility supporting customers, partners, and industry peers through automated storage, efficient sample tracking, data accuracy, and access to sample inventory. The Central Compound Management (CCM) System would enable our customers to manage the storage, profiling, and distribution of compounds seamlessly, thereby improving efficiency and reducing technical/operational errors and time lags in projects. For more information on our compound management services, visit the link in the comments section 🔗 . #Syngene #CCM #CMS #drugdiscovery

⭐Introducing SynSight – our "opt-in" data consortium designed to empower clients with enhanced predictive models for more informed decision-making in their projects. #SynSight offers a common platform for members to leverage learnings from larger volumes of standardized data while protecting proprietary information. This means faster, higher-quality decision-making, and a significantly shortened design-make-test-analyze (DMTA) cycle. Join the SynSight community today and start making data-driven decisions with confidence! Download the brochure to know more about SynSight, link in the comments section 🔗 #SyngeneDrugDiscovery #DataConsortium #PredictiveModels #InformedDecisions

📌India Med Today has featured an article titled "The Blockbuster Biosimilar Drugs" highlighting the rise of biosimilar drugs in India as affordable alternatives to biologics. Sridevi Khambhampaty, VP – Biopharmaceutical Development, Syngene International shares insights on the safety and efficacy of biosimilar drugs compared to biologics, emphasizing their validation through extensive clinical studies. Sridevi also highlights the critical need for transparency in publishing comparability data and clinical experiences of Indian biosimilar manufacturers and clinicians. To read the full article, visit the link in the comments section🔗 #Syngene #biosimilardrugs #CDMO